Cover Image
市場調查報告書

非小細胞肺癌:KOL (關鍵意見領袖) 分析

NSCLC: KOL Insight [2017]

出版商 FirstWord 商品編碼 372761
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
非小細胞肺癌:KOL (關鍵意見領袖) 分析 NSCLC: KOL Insight [2017]
出版日期: 2017年08月01日 內容資訊: 英文
簡介

本報告以非小細胞肺癌 (NSCLC)的已上市13種藥物及開發階段的9種藥物為研究主題,提供北美及歐洲的12名關鍵意見領袖(KOL) 的各種見解彙整

已上市藥物

  • 免疫療法
    • Opdivo (nivolumab; BMS)
    • Keytruda (pembrolizumab; Merck & Co.)
  • EGFR變異陽性NSCLC
    • Gilotrif/Giotrif (afatinib; Boehringer Ingelheim)
    • Iressa (gefitinib; AstraZeneca)
    • Tarceva (erlotinib; Astellas)
    • Tagrisso (osimertinib; AstraZeneca)
  • ALK陽性NSCLC
    • Xalkori (crizotinib; Pfizer)
    • Zykadia (ceritinib; Novartis)
    • Alecensa (alectinib; Roche)
  • ALK、EGFR變異陰性NSCLC
    • Avastin (bevacizumab; Roche)
    • Vargatef (nintedanib; Boehringer Ingelheim)
    • Cyramza (ramucirumab; Eli Lilly)
    • Portrazza (necitumumab; Eli Lilly)

開發平台藥物

  • 免疫療法
    • Atezolizumab (RG7446:Genentech/Roche)
    • Durvalumab (MEDI4736:AstraZeneca)
    • Yervoy (Ipilimumab:BMS)
    • Avelumab (MSB0010718C/PF-06834635:Merck Group/Pfizer)
    • Plinabulin (NPI-2358:BeyondSpring)
  • EGFR變異陽性NSCLC
    • Rociletinib (CO-1686:Celgene Corporation/Clovis Oncology)
  • ALK陽性NSCLC
    • Brigatinib (AP26113:ARIAD)
  • ALK、EGFR變異陰性NSCLC
    • Abemaciclib (LY2835219:Eli Lilly)
    • Selumetinib (AZD6244:Array BioPharma/AstraZeneca)

調查範例

  • 改變第一選擇藥的PD-1/L1抑制劑
    • Keytruda、Opdivo的首位爭奪
    • CheckMate-026實驗結果Merck & Co.帶來決策的勝利嗎?等
  • 聯合治療的崛起
    • 數公司投資免疫治療藥的聯合治療
    • 利用的決定性因素是什麼?
    • 最成功的是什麼?
    • 能奪去單劑療法的地位嗎?
  • 對下游的影響
    • 部分KOL第一選擇藥的改革將改變第二選擇藥環境的指摘
    • 預測怎樣的影響效果?
    • 影響Opdivo的獨佔地位的是什麼?
  • 各種擴展
    • PD-1/L1 抑制劑的一部分:進行佐劑、第III環境的利用的評估
  • 治療流程的上升
    • KOL:成為第一選擇藥可能性的EGFR變異陽性、ALK陽性NSCLC治療藥受到關注等

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

How will immunotherapy combination regimens impact the NSCLC treatment landscape?

The pace of change in NSCLC shows no sign of abating. Developments in immunotherapy continue to take centre stage, particularly in first-line treatment. Merck & Co. have a head start in this setting with recent approvals for Keytruda; however, BMS, AstraZeneca, Roche and Merck Group/Pfizer still have much to play for. As fist-line treatment options expand, how will patients be selected for specific therapies, what role will combinations play, and how will these impact second-line treatment decisions? Targeted therapies also continue to generate much interest. KOLs weigh in on how data from the ALEX trial of Alecensa, and new product approvals, could shake up the treatment algorithm for ALK-positive NSCLC, as well as developments in EGFR-, BRAF- and ROS1-positive disease. In this report seven US and five EU KOLs offer candid insights on 12 marketed therapies and seven pipeline drugs.

Request sample pages

Take a tour of the report now:

  • Methodology >
  • Research Objectives >
  • Questions Asked >
  • See the NSCLC therapies covered >
  • Find out who the 7 US and 5 European KOLs are >
  • Sample Pages >

Top Takeaways

  • Immunotherapy has transformed front-line treatment options for NSCLC. How is first-line treatment anticipated to evolve, and what will inform treatment decisions, in the non-driver mutation space?
  • How do KOLs interpret the 21G data and the FDA approval of Merck & Co.'s Keytruda in combination with chemotherapy?
  • Biomarker testing and patient selection are set to become more sophisticated. How will they continue to develop and impact the NSCLC treatment algorithm?
  • How do KOLs rate the potential for AstraZeneca's durvalumab, and other PD1/L1 inhibitors, to be used in the treatment of stage III NSCLC?
  • How are the CheckMate-012 data and the potential for BMS' Opdivo plus ipilimumab to succeed as a first-line treatment viewed?
  • How do KOLs interpret the findings from the ALEX trial and how do they view the future for Roche's Alecensa as a potential first-line therapy for ALK-positive NSCLC?
  • What are the overall prospects for Takeda's Alunbrig and Pfizer's lorlatinib as treatments for ALK-positive NSCLC?

Request sample pages

Back to the top

Quotes

"I think you are going to see the biggest change in first-line metastatic NSCLC. In the last few months it has changed many times and it will continue to change because first line is where it is easiest to show a difference. Combination IOs will take over; IOs with chemotherapy will be there."EU Key Opinion Leader

"Patients will be getting NGS testing the vast majority of the time. We will get far more sophisticated about predicting which patients will benefit the most and least with immunotherapy and we'll see how we are using immunotherapy now as the dark ages compared to [in five years' time], like 1975 with chemotherapy." US Key Opinion Leader

Sample of therapies covered

Marketed Therapies

  • Keytruda (pembrolizumab; Merck & Co.)
  • Opdivo (nivolumab; Bristol-Myers Squibb)
  • Tecentriq (atezolizumab; Roche)
  • Tagrisso (osimertinib; AstraZeneca)
  • Xalkori (crizotinib; Pfizer/Merck Group)
  • Zykadia (ceritinib; Novartis)
  • Alecensa (alectinib; Roche)
  • Alunbrig (brigatinib; Takeda)
  • Vargatef (nintedanib; Boehringer Ingelheim)
  • Portrazza (necitumumab; Eli Lilly)
  • Cyramza (ramucirumab; Eli Lilly)
  • Tafinlar/Mekinist (dabrafenib/trametinib; Novartis)

Pipeline Therapies

  • Avelumab (Bavencio; Merck Group/Pfizer)
  • Durvalumab (Imfinzi; AstraZeneca)
  • Ipilimumab (Yervoy; Bristol-Myers Squibb)
  • Dacomitinib (PF-00299804; Pfizer)
  • Lorlatinib (PF-06463922; Pfizer)
  • Ensartinib (X-396; Xcovery)
  • OSE-2101 (Tedopi; OSE Immunotherapeutics)

KOLs Interviewed

KOLs from North America

  • Laura Q.M. Chow, Associate Professor, Medical Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, Seattle, WA
  • Leora Horn, Associate Professor of Medicine and Clinical Director, Thoracic Oncology Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN
  • Saad Khan, Assistant Professor, Medical Oncologist, Southwestern Medical Center, University of Texas, Dallas, TX
  • Jose I. Mayordomo, Professor, Medical Oncologist, Division of Medical Oncology, University of Colorado Hospital (UCH), Aurora, CO
  • Jared Weiss, Associate Professor, University of North Carolina at Chapel Hill, Clinical Research, Thoracic Oncology Program, Chapel Hill, NC
  • Howard West, Medical Oncologist and Medical Director of the Thoracic Oncology Program, Swedish Cancer Institute, Seattle, WA

KOLs from Europe

  • Siow Ming Lee, Professor of Medical Oncology, University College London, London, UK
  • Antonio Passaro, Medical Oncologist, Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy
  • Maurice Perol, Professor, Head of Thoracic Oncology, Medical Oncology Department, Leon Berard Cancer Center, Lyon, France
  • David Planchard, Associate Professor, Department of Medical Oncology (Thoracic Oncology Group), Gustave-Roussy, Villejuif, France
  • Anonymous German KOL, Medical Oncologist at a specialist pulmonary hospital, Germany

Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

  • Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date.
  • You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.

Money Back Guarantee

At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company's success.

FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Table of Contents

1. Executive summary

2. Research objectives

3. Research focus

  • 3.1 NSCLC treatment
    • 3.1.1 Treatment for early-stage NSCLC (stage I-IIIB)
    • 3.1.2 Treatment for advanced NSCLC (stage IV)

4. Report focus

5. Immunotherapies

  • 5.1 Approved drugs
    • 5.1.1 Keytruda (pembrolizumab; Merck & Co.)
    • 5.1.2 Opdivo (nivolumab; Bristol-Myers Squibb)
    • 5.1.3 Tecentriq (atezolizumab; Roche)
  • 5.2 Pipeline drugs
    • 5.2.1 Avelumab (Bavencio; Merck Group/Pfizer)
    • 5.2.2 Durvalumab (Imfinzi; AstraZeneca)
    • 5.2.3 Ipilimumab (Yervoy; Bristol-Myers Squibb)

6. EGFR mutation-positive NSCLC

  • 6.1 Approved drugs
    • 6.1.1 Tagrisso (osimertinib; AstraZeneca)
  • 6.2 Pipeline drugs
    • 6.2.1 Dacomitinib (PF-00299804; Pfizer)

7. ALK- and ROS1-positive NSCLC

  • 7.1 Approved drugs
    • 7.1.1 Xalkori (crizotinib; Pfizer/Merck Group)
    • 7.1.2 Zykadia (ceritinib; Novartis)
    • 7.1.3 Alecensa (alectinib; Roche)
    • 7.1.4 Alunbrig (brigatinib; Takeda)
  • 7.2 Pipeline drugs
    • 7.2.1 Lorlatinib (PF-06463922; Pfizer)
    • 7.2.2 Ensartinib (X-396; Xcovery)

8. ALK and EGFR mutation-negative NSCLC

  • 8.1 Approved drugs
    • 8.1.1 Vargatef (nintedanib; Boehringer Ingelheim)
    • 8.1.2 Portrazza (necitumumab; Eli Lilly)
    • 8.1.3 Cyramza (ramucirumab; Eli Lilly)
    • 8.1.4 Tafinlar/Mekinist (dabrafenib/trametinib; Novartis)
  • 8.2 Pipeline drugs
    • 8.2.1 OSE-2101 (Tedopi; OSE Immunotherapeutics)

9. Conclusion

10. Appendix

  • 10.1 KOL details
    • 10.1.1 KOLs from North America
    • 10.1.2 KOLs from Europe
Back to Top